减重赛道“人满为患”：中国药企试图“后来居上”？

大洋网2025-07-06

减重赛道已经是“人满为患”——老牌外资“双雄”诺和诺德的司美格鲁肽以及礼来的替尔泊肽在中国市场打得火热，线上线下平台都在积极铺货，原料药、产能问题也都在解决；与此同时，中国药企也试图“弯道超车”，掀起下一波治疗热点。对此，专家提醒，减重药物有适应症要求，消费者最好是遵医嘱或在药师指导下使用。到底应该如何评价市面上层出不穷的减重药物？复旦大学附属中山医院内分泌科主任医师、教授李小英表示，评价一款减重...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2549452325?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-06 10:22","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2549452325","market":"us","top_or_hot":-1,"title":"减重赛道“人满为患”：中国药企试图“后来居上”？","media":"大洋网","content":"<div>\n<p>减重赛道已经是“人满为患”——老牌外资“双雄”诺和诺德的司美格鲁肽以及礼来的替尔泊肽在中国市场打得火热，线上线下平台都在积极铺货，原料药、产能问题也都在解决；与此同时，中国药企也试图“弯道超车”，掀起下一波治疗热点。对此，专家提醒，减重药物有适应症要求，消费者最好是遵医嘱或在药师指导下使用。到底应该如何评价市面上层出不穷的减重药物？复旦大学附属中山医院内分泌科主任医师、教授李小英表示，评价一款减重...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250706104910979b89d0&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>减重赛道“人满为患”：中国药企试图“后来居上”？</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n减重赛道“人满为患”：中国药企试图“后来居上”？\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-06 10:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250706104910979b89d0&s=b><strong>大洋网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>减重赛道已经是“人满为患”——老牌外资“双雄”诺和诺德的司美格鲁肽以及礼来的替尔泊肽在中国市场打得火热，线上线下平台都在积极铺货，原料药、产能问题也都在解决；与此同时，中国药企也试图“弯道超车”，掀起下一波治疗热点。对此，专家提醒，减重药物有适应症要求，消费者最好是遵医嘱或在药师指导下使用。到底应该如何评价市面上层出不穷的减重药物？复旦大学附属中山医院内分泌科主任医师、教授李小英表示，评价一款减重...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250706104910979b89d0&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0203201768.USD","symbol_name":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250706104910979b89d0&s=b","article_id":"2549452325","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250706104910979b89d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2549452325","pubTimestamp":1751768520,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"减重赛道已经是“人满为患”——老牌外资“双雄”诺和诺德的司美格鲁肽以及礼来的替尔泊肽在中国市场打得火热，线上线下平台都在积极铺货，原料药、产能问题也都在解决；与此同时，中国药企也试图“弯道超车”，掀起下一波治疗热点。据悉，玛仕度肽可用于成人肥胖或超重患者的长期体重控制，这是全球首个获批的GCG/GLP-1双受体激动减重药物。替尔泊肽可改善中度至重度阻塞性睡眠呼吸暂停肥胖成人患者的睡眠障碍。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","BK4007":"制药","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","BK4599":"减肥药","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","BK4581":"高盛持仓","LU0238689110.USD":"贝莱德环球动力股票基金","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","BK4585":"ETF&股票定投概念","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4534":"瑞士信贷持仓","LU0882574139.USD":"富达环球消费行业基金A ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","BK4516":"特朗普概念","LLY":"礼来","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","NVO":"诺和诺德","LU2063271972.USD":"富兰克林创新领域基金","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","01801":"信达生物","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"The weight loss track is \"overcrowded\": Chinese pharmaceutical companies are trying to \"catch up\"?","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":0.9,"NVO":0.9,"LLY":0.9},"content_text":"减重赛道已经是“人满为患”——老牌外资“双雄”诺和诺德的司美格鲁肽以及礼来的替尔泊肽在中国市场打得火热，线上线下平台都在积极铺货，原料药、产能问题也都在解决；与此同时，中国药企也试图“弯道超车”，掀起下一波治疗热点。对此，专家提醒，减重药物有适应症要求，消费者最好是遵医嘱或在药师指导下使用。到底应该如何评价市面上层出不穷的减重药物？复旦大学附属中山医院内分泌科主任医师、教授李小英表示，评价一款减重药效果的维度非常多元，对于中国患者来说，能够实现10%的减重幅度是基础。在减重幅度之外，还需要综合这款药物的安全性、能否改善肥胖相关合并症、减重时的减肌比例、未来反弹情况等不同指标。中国药企齐齐发力7月3日，刚刚获批的信达生物旗下减重创新药物玛仕度肽注射液（商品名：信尔美®）在美团医药健康旗下美团自营大药房首发上线。据悉，玛仕度肽可用于成人肥胖或超重患者的长期体重控制，这是全球首个获批的GCG/GLP-1双受体激动减重药物。该药物此前在全球范围内开展了多项临床研究，有结果显示治疗20周减重降幅最高可达21%。降糖适应症预期也将在不久后获批。备受业界关注的是国产药物此次治疗一大热点——“燃脂”。玛仕度肽双靶作用机制相较GLP-1单靶药物既能够增加减重效果，又能够降低内脏脂肪含量高达80%，并对高血压、高血糖、高血脂、高尿酸等代谢问题有明显改善。据悉，除了此次获批的适应症外，玛仕度肽另外一项降糖适应症预计也将在不久之后获批。记者获悉，玛仕度肽已经陆续在各个销售渠道铺货。在业界看来，信达生物等国内创新药企业此次在渠道上也打开了思路，通过布局如美团自营大药房等医药电商等极具国内特色的线上渠道，以期在持续攀升市场中抢占更多份额。美团方面也表示，希望积极助力国产创新药增进大家的健康消费。此外，就在7月1日，翰宇药业发布今年半年利润的业绩预告称：2025年上半年，公司预计实现归母净利润1.42亿-1.62亿元，同比增幅高达1470%-1664%；扣非净利润1.22亿元-1.42亿元，同比增长304.27%-337.76%。值得注意的是，翰宇药业能做到这一步实在不容易，公司曾陷于扣非净利润亏损长达7年之久，这还是首次实现扭亏为盈。翰宇药业将最大功臣归于其“减重神药”利拉鲁肽注射液仿制药的出海成功以及原料药的国际收入和成本控制等。去年12月，其仿制的利拉鲁肽注射液在美国上市，并和美国合作伙伴Hikma采取“低出货价+高利润分成的BD”模式。外资药企进军新赛道与此同时，外资药企也并没有“坐等”后来者赶超，而是在不断开拓进军新赛道。就在2025年6月30日，礼来宣布穆峰达®（替尔泊肽注射液）获得中国国家药品监督管理局批准，成为首个且目前唯一用于治疗成人肥胖患者的中度至重度阻塞性睡眠呼吸暂停（OSA）的处方药。替尔泊肽可改善中度至重度阻塞性睡眠呼吸暂停肥胖成人患者的睡眠障碍。该适应症的使用需在控制饮食和增加运动基础上进行。据悉，除了改善睡眠呼吸暂停症状外，接受替尔泊肽治疗的成人患者平均体重减轻了18.1%，同时接受替尔泊肽和PAP治疗的成人患者平均体重减轻了20.1%；而安慰剂组的成人患者平均体重分别减轻了1.3%和2.3%。替尔泊肽的安全性和耐受性与此前试验中报告的替尔泊肽安全性一致。最常见的不良事件是胃肠道不良事件，程度为轻至中度。未来中国的GLP-1市场容量究竟有多大？新近上市产品的市场表现可以成为一个观察窗口。“减肥产品的定价比较高，主要是中高端人群使用，且国产药品的上市时间晚于外资。此时，市场的认可度就决定了国产GLP-1的未来发展空间。”医疗战略咨询公司Latitude Health创始人赵衡这样表示。文/广州日报新花城记者：涂端玉广州日报新花城编辑：李光曼[ 编辑： gzck ]","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2549452325","isCrawlerRequest":true}